
|Articles|July 1, 2004
ISTA seeks bromfenac OK; gets nod for injected hyaluronidase
Irvine, CA-ISTA Pharmaceuticals Inc. is seeking FDA approval of its bromfenac sodium ophthalmic solution 0.1% (Xibrom) for the treatment of ocular inflammation following cataract surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5




























